Emerging Paradigms in Immune-Focused Drug Discovery

  • ACS Med Chem Lett. 2026 Feb 23;17(3):631-633. doi: 10.1021/acsmedchemlett.6c00079.
Anna C Renner  1 ,  Robert B Kargbo  2
Affiliations
  • 1. North Dakota State University, Fargo, North Dakota 58108-6050, United States.
  • 2. Independent Research Consultant, Middleton, Wisconsin 53562, United States.
PMID: 41847655 DOI: 10.1021/acsmedchemlett.6c00079
Abstract

Recent patent disclosures highlight a conceptual shift in drug discovery, integrating targeted protein degradation with functional precision oncology. IRAK-M and IRAK4 degraders exemplify how innate immune signaling can be rewired through selective protein removal, while patient-derived microcancer platforms provide a decision framework for rationally deploying such agents. Together, these inventions redefine how molecular precision and biological context converge to guide translational success.

Products